Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group

BACKGROUND: This study evaluated the safety and efficacy of nab-paclitaxel as second-line treatment in patients with advanced gastric adenocarcinoma. METHODS: Thirty-nine pretreated patients [33 with taxane-based regimens (docetaxel, cisplatin, and fluorouracil)] and 6 with combination of fluoropyri...

Descripción completa

Detalles Bibliográficos
Autores principales: Katsaounis, Panagiotis, Kotsakis, Athanasios, Kentepozidis, Nikolaos, Polyzos, Aris, Bakogeorgos, Marios, Koinis, Filippos, Vamvakas, Lambros, Vardakis, Nikolaos, Kalbakis, Kostas, Boukovinas, Ioannis, Varthalitis, Ioannis I., Prinarakis, Efthimios, Georgoulias, Vassilis, Souglakos, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Gastroenterology 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759614/
https://www.ncbi.nlm.nih.gov/pubmed/29333068
http://dx.doi.org/10.20524/aog.2017.0215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759614/
https://www.ncbi.nlm.nih.gov/pubmed/29333068
http://dx.doi.org/10.20524/aog.2017.0215

Ejemplares similares